Gene copy number changes, cancer stem cell (CSC) increases, and platinum chemotherapy resistance contribute to poor prognosis in patients with recurrent high grade serous ovarian cancer (HGSOC). CSC phenotypes involving Wnt-b-catenin and aldehyde dehydrogenase activities, platinum resistance, and tumor initiating frequency are here associated with spontaneous genetic gains, including genes encoding KRAS, MYC and FAK, in a new murine model of ovarian cancer (KMF). Noncanonical FAK signaling was sufficient to sustain human and KMF tumorsphere proliferation, CSC survival, and platinum resistance. Increased FAK tyrosine phosphorylation occurred in HGSOC patient tumors surviving neoadjuvant platinum and paclitaxel chemotherapy and platinum resistant tumorspheres acquired FAK dependence for growth. Importantly, combining a pharmacologic FAK inhibitor with platinum overcame chemoresistance and triggered apoptosis in vitro and in vivo. Knockout, rescue, genomic and transcriptomic analyses collectively identified more than 400 genes regulated along a FAK/b-catenin/Myc axis impacting stemness and DNA repair in HGSOC, with 66 genes gained in a majority of Cancer Genome Atlas samples. Together, these results support combinatorial testing of FAK inhibitors for the treatment of recurrent ovarian cancer. 
, and David D. Schlaepfer Introductionbe distinct from FAK inhibition, since kinase-inactive FAK retains important scaffolding functions (Lim, Chen et al., 2008) .
Several ATP-competitive FAK inhibitors have been developed and have displayed acceptable Phase I safety profiles in patients with advanced solid tumors (Hirt, Waizenegger et al., 2018 , Jones, Siu et al., 2015 , Soria, Gan et al., 2016 . Phase II trials with FAK inhibitors have yielded some complete responses and many patients exhibiting stable disease. Current combinatorial approaches with FAK inhibitors are being tested in patients with pancreatic, mesothelioma, and non-small cell lung carcinoma. In ovarian and prostate carcinoma mouse tumor models, FAK inhibition (VS-6063, defactinib) enhanced taxane-mediated tumor apoptosis (Kang, Hu et al., 2013 , Lin, Lee et al., 2018 . Additionally, inhibitors of FAK and Myc exhibit combinatorial activity in promoting HGSOC apoptosis in vitro (Xu, Lefringhouse et al., 2017) . It remains uncertain whether gains in 8q24 encompassing PTK2 are associated with specific HGSOC cell phenotypes or responses to therapy, as determinants of FAK pathway dependence in tumors remain unknown.
Herein, we molecularly characterize a new murine model of ovarian cancer that displays spontaneous gains in the K-Ras, Myc, and FAK genes among other striking similarities to human ovarian carcinoma cell phenotypes. By using a combination of genetic FAK knockout and rescue, pharmacological inhibition, sequencing and bioinformatics, we identify a non-canonical FAK activity-dependent linkage to b-catenin and Myc leading to differential mRNA target expression supporting CSC survival and platinum resistance. Our studies linking intrinsic FAK activity to platinum resistance support the combinatorial testing of FAK inhibitors for recurrent ovarian cancer.
Results

A new in vivo evolved murine epithelial ovarian cancer model
HGSOC is characterized by p53 mutation or loss and common genomic copy number alterations, yet no preclinical models exist to study connections between genomic gains or losses with cell phenotypes. Murine ID8 cells are spontaneously-immortalized clonal ovarian epithelial cells that can form tumors in normal C57Bl6 mice (Roby, Taylor et al., 2000) . ID8 cells do not contain common oncogenic mutations, express wild type p53, and p53 inactivation enhances ID8 tumor growth and increases sensitivity to platinum chemotherapy (Walton, Blagih et al., 2016 , Walton, Farquharson et al., 2017 . Passage of ID8 cells through C57Bl6 mice can enhance ID8 tumorigenic potential via uncharacterized mechanisms (Clark, Gupta et al., 2016 , Mo, Bachelder et al., 2015 , Ward et al., 2013 .
We previously isolated aggressive ID8-IP cells, lethal in mice within 40 versus 90 days compared to parental ID8 cells (Ward et al., 2013) , via early recovery of ascitesassociated cells and anchorage-independent expansion ex vivo (Fig. 1A) . Total exome sequencing (90% of exons sequenced at 100X) of ID8 and ID8-IP cells revealed 19619 shared, 29373 ID8 unique, and 11800 ID8-IP unique gene variants (Supplemental Fig. S1 and Supplemental Tables S1-S3). However, less than 1% of exon variants identified were detected as mRNAs by RNA sequencing (~60 million clean reads/replicate). No murineequivalent mutations were found in COSMIC, the Catalogue of Somatic Mutations in Cancer. In addition to ID8 non-synonymous mutations previously identified (Walton et al., 2016) , we detected two additional potential damaging mutations in HJURP (Supplemental Fig. S1 ). In ID8-IP cells, after filtering for transcribed variants and subtracting for mutations found in the Single Nucleotide Polymorphism database (dbSNP138), predicted damaging mutations were identified in XXYLT1 and ATXN10 (Supplemental Fig. S1C ). Overall, the mutational burden in ID8-IP cells is low.
To determine if gene copy number alterations underlie ID8-IP phenotypes, exome sequencing read values and bioinformatic analyses were used to map sites of DNA gains or loss across chromosomes using ID8 as a reference (Fig. 1B) . Gains in murine chromosome cytoband regions 6qD1-G3, 15qD3-F3, and 15qA1-D3 were present in ID8-IP cells ( Figure 1B , green circles). These correspond to human cytobands 12p12.1, 8q24.2, and 8q24.3, with the latter two representing one of the most amplified regions in HGSOC (Cancer Genome Atlas Research, 2011 , Li et al., 2019 . The gain in cytoband 15qA1-D3 is in addition to chromosome 15 polyploidy detected by ID8 karyotype analyses (Roby et al., 2000) . Notably, common gene gains in ID8-IP and HGSOC include KRAS, MYC, and PTK2 (encoding FAK) that support proliferation, stem cells, and adhesion signaling, respectively (Table I) . Herein, these ID8-IP cells will be termed KMF to denote gains in K-Ras, Myc, and FAK genes. Murine KMF cells contain several gains or losses in genes common to the top 20 set of genes altered in HGSOC (Table I and Supplemental  Table S4 ).
MYC and PTK2 associations in HGSOC
In HGSOC, KRAS, MYC, and PTK2 gains co-occur in 42% of tumors and PTK2 plus MYC co-occur in an additional 32% of HGSOC patients (Fig. 1C) . More than 70% of HGSOC tumors contain combined gains at PTK2 and MYC loci. Although MYC has oncogenic properties (Kumari et al., 2017) , MYC copy number gains are not strongly correlated with increased MYC mRNA or protein levels in HGSOC patient tumors (Supplemental Figs. S2) . By contrast, PTK2 copy number gains are linearly proportional to increased FAK mRNA (R 2 = 0.66) and FAK protein (R 2 =0.61) levels in HGSOC (Supplemental Figs. S2). Elevated FAK mRNA levels are associated with decreased HGSOC patient relapse-free survival (n = 1435, P = 0.0009, and hazard ratio = 1.25) (Fig.  1D) . Bioinformatic analyses identified a set of 36 genes on different chromosomes in HGSOC that exhibit a significant and at least a two-fold change in tumors with elevated PTK2 (Supplemental Table S5 ). This 36 gene set was associated with a significant shorter time to relapse (n = 575, P = 0.0024, and hazard ratio = 1.37) (Fig. 1E) . Together, these results support the importance of PTK2 gains, and indirectly FAK protein, in promoting HGSOC tumor progression.
KMF cells exhibit enhanced CSC phenotypes and cisplatin resistance
KMF cells also contain regions of chromosome loss that correspond to regions frequently eliminated in HGSOC encompassing GNA11, MAP2K2, TJP3, MAP3K1, CCNB1, PIK3R1, and FOXD1 genes (Table 1) . Additionally, a mutation in TRP53 exon 11 encoding the 3' untranslated region and two p53 mRNA splice variants were detected within KMF cells (Supplemental Fig. S3 ). Immunoblotting did not detect p53 protein expression in KMF cells compared to ID8 and murine Lewis lung carcinoma cells containing wildtype p53. Several p53 target mRNAs were decreased in KMF compared to ID8 cells under 3D conditions by quantitative real-time PCR (Supplemental Fig. S3) . Surprisingly, KMF cells exhibit constitutively-elevated p21CIP1 protein, a known target of p53 transcriptional activity (Supplemental Fig. S3 ). However, deregulated p21CIP1 levels can be indicative of a p53-deficient environment (Georgakilas, Martin et al., 2017) . RNA sequencing did not detect expression of Cdkn2a (p16/INK4A) or Cdkn2b (p15/INK4B), which impact p53 protein stability and cell transformation (Al-Khalaf & Aboussekhra, 2018) . We conclude that KMF cells are de facto deficient in p53 regulation.
KMF cells possess a mesenchymal-like morphology compared to the epithelial-like growth of ID8 cells in 2D culture (Supplemental Fig. S4 ). KMF cells form more 3D tumorspheres ( Fig. 1F ) and colonies in methylcellulose than ID8 cells (Fig. 1G) . RNA sequencing revealed 10800 shared, 744 ID8 enriched, and 402 KMF enriched transcripts with FPKM (Fragments Per Kilobase of transcript per Million mapped read) values > 1 (Supplemental Fig. S4 and Supplemental Table S6 ). KMF tumorspheres exhibit target enrichment in Cell Cycle, Mitotic Spindle Checkpoint, and DNA Repair pathways (Supplemental Figs. S4) . At the protein level, KMF tumorspheres expressed elevated FAK, increased FAK pY397, but decreased E-cadherin and b-catenin levels relative to ID8 cells (Fig. 1H) . Although KMF cells expressed lower b-catenin protein levels, b-catenin transcriptional activity was greatly elevated in KMF compared to ID8 cells grown as tumorspheres (Fig. 1I) . As FAK and b-catenin are co-regulators of CSC phenotypes in breast carcinoma cells (Kolev, Tam et al., 2017) , ID8 and KMF cells were analyzed for changes in ALDH activity and intrinsic CP resistance. KMF tumorspheres exhibited increased ALDH activity (Figs. 1J and K) and were more resistant to cisplatin (CP) -induced toxicity than ID8 cells (Fig. 1L) . The enhanced CSC phenotypes and intrinsic CP chemoresistance of KMF cells remained after extended passage. Taken together, this new KMF model exhibits noteworthy similarities to HGSOC. FAK pY397 remains elevated in ovarian carcinoma tumors surviving neoadjuvant chemotherapy A subset of HGSOC patients are treated with neoadjuvant carboplatin and paclitaxel chemotherapy to reduce tumor burden prior to surgery (Matulonis et al., 2016) . However, some tumor cells, such as CSCs, escape CP-mediated apoptosis and survive chemotherapy (Wiechert et al., 2016) . FAK protein and FAK tyrosine phosphorylation (pY397 FAK) levels are elevated in primary HGSOC tumors compared to normal tissue ), but it is not known whether chemotherapy alters FAK activation. To evaluate this, paired primary biopsies and tumors obtained at the time of cytoreductive surgery following neoadjuvant carboplatin and paclitaxel chemotherapy were analyzed by immunohistochemical (IHC) staining and quantitative image analyses (Supplemental Table  S3 and Supplemental Fig. S5) . A high degree of Pax8 and pY397 FAK co-localized staining was detected ( Fig. 2A) with FAK pY397 exhibiting both cytoplasmic and nuclear localization. Many of these tumor cells were positive for the Ki-67 proliferation marker. Validation was obtained using a pY397 FAK peptide block (Supplemental Fig. S5 ) and FAK pY397 staining was objectively higher in ovarian tumor compared to stromal cells (Fig. 2B ). Among tissue samples obtained after neoadjuvant chemotherapy, Pax8 and pY397 FAK staining remained highly co-localized within residual tumors (Fig. 2C and Supplemental Fig. S5) . Surprisingly, by comparing samples from the same patients, pY397 FAK staining after neoadjuvant chemotherapy in residual tumor cells was significantly increased (Fig. 2D) .
Increased FAK pY397 is generally considered a marker for elevated cell adhesion or tissue stiffness . Unexpectedly, elevated pY397 FAK staining was also observed within ascites Pax-8 positive tumorspheres that displayed active bcatenin staining (Fig. 2E) . This was unanticipated, since FAK Y397 phosphorylation is rapidly lost when human platinum resistant OVCAR3 cells are removed from adherent 2D culture and held in suspension (Fig. 2F) . However, an extended time course analyses of OVCAR3 cells placed in anchorage-independent defined media conditions (PromoCell XF) revealed that FAK Y397 phosphorylation was restored as OVCAR3 cells clustered to form tumorspheres within 2-3 days (Figs. 2F and G) . Surprisingly, CP (1 µM) treatment of OVCAR3 tumorspheres (EC50 > 10 µM) also resulted in increased FAK Y397 and bcatenin Y142 phosphorylation (Fig. 2H) . As b-catenin Y142 is a direct FAK substrate promoting b-catenin activation in endothelial cells (Chen, Nam et al., 2012) , our findings support the notion that non-canonical FAK activation occurs during tumorsphere formation and in response to CP stimulation.
Combinatorial effects of CP and FAK inhibition
As CP treatment increased FAK Y397 phosphorylation, and since FAK activation was associated with more aggressive phenotypes in patient tumors and in KMF cells, we next investigated the effect of low dose CP treatment (1 µM) in the presence or absence of FAK inhibition (VS-4718, 1 µM) over 5 days on tumorsphere formation, ALDH activity, and viability of OVCAR3 and KMF cells (Figs. 3A-C) . Cisplatin EC50 values for growth inhibition were 13 µM and 31 µM for OVCAR3 and KMF tumorspheres, respectively. CP treatment resulted in increased tumorsphere formation and ALDEFLUOR activity of OVCAR3 and KMF cells, consistent with this being an activation-type stress. In contrast, FAK inhibitor (FAKi or VS-4718, 1 µM) treatment significantly reduced tumorsphere formation and ALDEFLUOR activity compared to control OVCAR3 and KMF cells (Figs. 3A and B) .
FAKi was not directly cytotoxic, since only CP combined with FAKi reduced tumorsphere viability (Fig. 3C ). Single agent CP or FAKi treatment did not alter KMF (Supplemental Fig. S6 ) or OVCAR3 (Supplemental Fig. S7 ) growth or viability in 2D culture. FAKi treatment inhibited FAK Y397 phosphorylation in 2D culture, but this did not impact 2D cell growth. Under 3D conditions, FAKi similarly reduced FAK Y397 phosphorylation, and was associated with an elevated percentage of KMF and OVCAR3 cells in G1 phase of the cell cycle, but alone did not trigger apoptosis (Supplemental Figs. S6 and S7) . The finding that FAKi decreased 3D, but not 2D cell proliferation, and that FAKi exhibits combinatorial activity with low-dose CP to promote cell apoptosis is consistent with a non-canonical role of context-dependent FAK signaling supporting tumorsphere growth and survival.
Constitutive FAK activity is connected to acquired CP-resistant phenotypes Phosphoinositide 3-kinase (PI3K)-elicited Akt activation is one of several survival signaling pathways downstream of FAK . More than half of HGSOC harbor genetic lesions that can elevate PI3K activity (Hanrahan, Schultz et al., 2012) . A2780 human ovarian carcinoma tumor cells contain activating mutations in PI3KCA and inactivation of PTEN -alterations that can promote Akt activation (Domcke, Sinha et al., 2013) . OVCAR10 cells similarly exhibit elevated Akt phosphorylation. Both A2780 and OVCAR10 cells are resistant to FAKi (1 µM) effects on 3D cell proliferation (Tancioni et al., 2014) . To determine if in vitro acquisition of increased CP resistance alters responses to FAKi, intermittent CP exposure (10 µM) and cell recovery was used to generate OVCAR10-CP and maintain A2780-CP70 cells (Godwin, Meister et al., 1992) . Both A2780-CP70 (EC50 = 60 µM) and OVCAR10-CP (EC50 = 9 µM) cells maintain elevated CP resistance and immunoblotting revealed constitutively-elevated FAK pY397 within tumorspheres of CP-resistant cells compared to parental cells (Fig. 3D) . Unexpectedly, CP-resistant A2780-CP70 and OVCAR10-CP cells exhibited a newly-acquired dosedependent sensitivity to FAKi growth inhibition as tumorspheres (Fig. 3E ), but not when the same cells were grown in 2D conditions (Supplemental Fig. S8 ).
Pharmacological FAK inhibition of A2780-CP70 and OVCAR10-CP tumorsphere growth was accompanied by an increased number of cells in G1 phase of the cell cycle (Fig. 3F) , decreased cyclin D1 expression, but not increased apoptosis (Supplemental Fig.  S8 ). FAKi prevented A2780-CP70 and OVCAR10-CP methylcellulose colony formation (Fig. 3G ), but FAKi had no effect on parental A2780 or OVCAR10 colony formation (Supplemental Fig. S8 ). An alternate FAKi (VS-6063, defactinib) also prevented A2780-CP70 colony formation in a dose-dependent manner (Supplemental Fig. S9 ). Both A2780-CP70 and OVCAR10-CP tumorspheres exhibited increased ALDH activity compared to parental cells and this was dependent on FAK activity (Supplemental Fig. S10 ).
OVCAR10-CP colony formation was evaluated in the presence of DMSO (control), FAKi, CP, or FAKi and CP to evaluate whether acquired sensitivity to FAKi could impact responses to CP treatment (Fig. 3H) . Single agent FAKi reduced colony size (Fig. 3I) , consistent with an inhibitory effect on tumorsphere proliferation (Figs. 3E and F) . The combination of FAKi with CP prevented colony formation (Figs. 3H and I) and was associated with increased OVCAR10-CP apoptosis (Fig. 3J) . Increased A2780-CP70 apoptosis also occurred only in the presence of FAKi and CP (Fig. 3J) . As OVCAR10-CP cells pre-treated with FAKi had a reduced ability to form methylcellulose colonies (Fig. 3K) , our results point to the importance of FAK activity in promoting elevated ALDH levels and CSC phenotypes in PI3KCA-and PTEN-mutated A2780-CP70 and OVCAR10-CP cells as part of adaptive changes associated with acquired CP resistance.
FAK inhibition prevents KMF CSC survival in vivo
ALDH activity and secondary tumor initiation frequency (TIF) are reporters used to identify CSCs (Raha et al., 2014) . Previous studies with triple-negative breast carcinoma models showed that FAKi (VS-4718) triggered CSC apoptosis (Kolev et al., 2017) . As FAKi treatment prevents KMF tumorsphere associated ALDH activity independent of apoptosis ( Fig. 3) , we next tested KMF secondary TIF capability after treating KMF tumor-bearing mice with VS-4718 (50 mg/kg, BID) for 21 days (Figs. 4A-D) . Tumor formation and the presence of mCherry-labeled KMF cells in peritoneal ascites were reduced by FAKi (Supplemental Fig. S11 ). FAK Y397 phosphorylation was similarly suppressed in ovarian tumors in response to oral FAKi administration ( Increased FAK pY397 and CP resistance after chemotherapy KMF tumorspheres exhibited increased FAK Y397 and elevated intrinsic CP resistance ( Fig. 1) . After carboplatin and paclitaxel neoadjuvant chemotherapy, HGSOC patient tumors similarly exhibited elevated FAK Y397 phosphorylation (Fig. 2) . KMF tumor bearing mice were treated with CP and paclitaxel (CPT) chemotherapy to determine if elevated FAK Y397 phosphorylation after chemotherapy was associated with increased CP resistance. This treatment acted to limit, but did not prevent, KMF tumor growth (Fig. 4E ). Re-isolation and expansion of peritoneal KMF cells from vehicle (V) or CPT treated mice followed by immunoblotting ( Fig. 4F ) revealed an increase increased pY397 FAK within KMF cells from tumor bearing mice that received CPT relative to vehicle treated control. Moreover, KMF cells from CPT-treated mice exhibited elevated CP resistance in vitro (Fig.  4G ). Taken together, these results support a link between increased FAK pY397 and in vivo acquired CP resistance.
FAK inhibition re-sensitizes CP resistant A2780-CP70 tumors to CPT chemotherapy
DTomato plus luciferase-labeled A2780 or A2780-CP70 cells were orthotopically injected into mice to assess the combinatorial potential of FAKi (VS-4718) and CPT chemotherapy on paired CP sensitive and CP resistant tumors. After tumors were established, CPT or FAKi, or both, were used as chemotherapy. A2780 tumor growth was insensitive to FAKi (Supplemental Fig. S12 ), consistent with limited FAKi effects on A2780 growth in vitro. In dramatic contrast, single-agent FAKi treatment reduced A2780-CP70 tumor growth approximately 40% compared to controls (Figs. 4H-K), suggesting that these CP resistant tumors acquire a FAK dependence. Flow cytometry analyses of peritoneal dTomatolabeled cells of tumor-bearing mice revealed that FAKi treatment selectively decreased ALDH activity in A2780-CP70, but not A2780, cells in vivo (Supplemental Fig. S13 ). This parallels the results obtained in the tumorsphere models ( Fig. 3 ) and confirms that A2780-CP70 tumor growth, and signals regulating ALDH activity, are FAK dependent.
As expected, the growth of platinum-sensitive A2780 tumors is prevented by CPT chemotherapy (Supplemental Fig. S12 ), whereas final A2780-CP70 tumor burden after CPT treatment was only slightly less than untreated controls (Figs. 4H-K). Interestingly, CPT treatment increased FAK Y397 phosphorylation (Figs. 4L and M) and ALDH-1A1 positive staining (Fig. 4N ) in non-necrotic regions of A2780-CP70 tumors (Supplemental Fig. S14 ). We hypothesized that gains in pY397 FAK and ALDH after CPT treatment may reflect FAK-dependent A2780-CP70 tumor cell survival signaling. Testing this hypothesis, we found that adding FAKi to CPT chemotherapy prevented A2780-CP70 tumor growth concurrent with suppression of FAK Y397 phosphorylation, loss of ALDH-1A1 expression, and tumor apoptosis in vivo . Together, these results show that FAK inhibition acts to re-sensitize CP-resistant A2780-CP70 tumors to CPT chemotherapy.
PTK2 inactivation alters CSC phenotypes and CP resistance
As pharmacological FAK inhibition combined with CP resulted in CP-resistant tumor cell apoptosis in vitro and in vivo, we used CRISPR/Cas9 genetic targeting to introduce frameshift changes in human OVCAR3 PTK2 exon 3 to create a FAK knockout (FAK-/-) model of HGSOC. Several FAK-/-clones were identified by immunoblotting and PTK2 exon 3 inactivation was verified by DNA sequencing (Fig. 5A ). Two clones (AB21 and AB28) were chosen for further characterization. OVCAR3-AB21 an -AB28 grew normally in 2D cell culture (Fig. 5B ), but did not grow colonies in methylcellulose when seeded as single cells compared to parental OVCAR3 cells (Figs. 5B and C). However, when cultured in serum-free tumorsphere media over 5 days, parental OVCAR3 and OVCAR3 FAK-/-AB21 cells exhibited similar metabolic activity and viability (Fig. 5D) .
Sustainability of OVCAR3 FAK-/-AB21 cells in 3D culture permitted a comparative evaluation of OVCAR3 cell sensitivities to different pharmacological inhibitors in a FAKdependent manner. As measured by a fluorescent indicator of aerobic cell respiration, FAK-/-cell viability was inhibited in the presence of low dose CP, the bromodomain inhibitor JQ1, and the Aurora A kinase inhibitor MLN8237, but not the MEK1 inhibitor U0126 or the PI-3'kinase inhibitor wortmannin (Fig. 5D ). JQ1 and FAKi can exhibit combinatorial inhibitory effects , while Aurora A can function to promote ovarian carcinoma adhesion and migration (Do, Xiao et al., 2014) ; pathways notably associated with FAK activation (Kleinschmidt and Schlaepfer, 2017) . FAK-/-OVCAR3 cells exhibited increased cytotoxicity to methyl 3-(4-methylphenyl) sulfonyl amino-benzoate (MSAB), a small molecule promoting b-catenin degradation and inhibition of Wntdependent tumors (Hwang, Deng et al., 2016 ) (Supplemental Fig. S15 ). These results support the importance of b-catenin in OVCAR3 tumorsphere survival. Moreover, genetic FAK inactivation fosters sensitivity to pharmacological agents that target signaling pathways commonly impacting Myc gene expression or Myc protein stability (Fig. 5E ) (Chen, Liu et al., 2018) .
As AB21 FAK-/-cells are clonal, these cells were reconstituted with GFP-tagged FAK to establish causality with FAK-/-phenotypes (Fig. 5F ). Immunoblotting of cell lysates showed that active b-catenin (not phosphorylated at Ser33/37/Thr41) and Myc levels were restored by GFP-FAK re-expression in OVCAR3 FAK-/-tumorspheres. Reduced b-catenin and Myc within OVCAR3 FAK-/-AB21 cells is consistent with the sensitivity of these cells to CP-, JQ1-, and MLN8237-induced cytotoxicity. GFP-FAK promoted tumorsphere formation, rescued ALDH activity, and restored ALDH-1A2 and ALDH-1B1 protein levels in OVCAR3 FAK-/-AB21 cells (Figs. 5G-J). FAK knockout resulted in an approximate 10-fold reduction in OVCAR3 tumorsphere EC50 to CP (Fig. 5K) . Notably, GFP-FAK expression rescued FAK-/-sensitivity to CP. These results show that FAK promotes OVCAR3 CSC phenotypes and CP resistance.
KMF FAK inactivation and reconstitution link intrinsic FAK activity to b-catenin
Since KMF tumorspheres exhibit elevated b-catenin activity and CSC phenotypes (Fig. 1) , CRISPR/Cas9 targeting was next used to inactivate the murine PTK2 exon 4 in KMF cells. Sanger sequencing confirmed unique deletions/ insertions predicted to terminate FAK protein translation in each of four PTK2 alleles identified in KMF cells (Supplemental Fig.  S16 ). Exome sequencing of FAK-/-clone KT13 (90% of exons sequenced at 100X) detected only 165 unique variants, including the four PTK2 alterations, indicating that CRISPR targeting was specific and that the KT13 genome is similar to KMF cells (Supplemental Table S8 ). CRISPR editing eliminated expression of FAK, but not the closely related kinase Pyk2 (Fig. 6A) . FAK-/-KT13 cells exhibited sensitivity to CP-, MLN8237-, or MSAB-induced cytotoxicity (Fig. 6B ) and displayed altered total b-catenin protein levels compared to actin (Fig. 6A) . Together, our studies support a connection between FAK, b-catenin, and Myc in both OVCAR3 and KMF cells.
As pharmacological FAK inhibition blocked KMF CSC phenotypes in vitro and in vivo (Figs. 3 and 4) , a GFP-FAK point mutant (R454) eliminating FAK kinase activity or GFP-FAK wildtype (WT) were stably-expressed in KMF FAK-/-KT13 cells (Fig. 6C) . In 3D anchorage-independent conditions, GFP-FAK WT but not GFP-FAK R454 was phosphorylated at Y397 (Fig. 6C) , thus implicating intrinsic kinase activity in FAK Y397 phosphorylation. Proteomic mass spectrometry analyses revealed elevated levels of extracellular matrix (Col6a1 and Lamb1), surface receptors (Pvrl2 and Cdh2), and b-catenin (Ctnnb1) in FAK-WT compared to FAK-/-(KO) and FAK-R454 cells ( Fig. 6D and Supplemental Table S9 ). These results support the importance of intrinsic FAK activity in maintaining b-catenin protein levels in KMF cells.
To test whether enhanced b-catenin signaling could complement FAK-/-KMF cell phenotypes, an activated b-catenin point-mutant (DGSK) lacking the regulatory GSK3b phosphorylation sites (Barth, Stewart et al., 1999) was stably expressed in FAK-/-KT13 cells (Fig. 6E) . b-catenin DGSK was over-expressed but not detected by antibodies to active b-catenin, likely due to disruption of the antibody epitope site (DGSK). FAK-/-KT13 cells did not form colonies in methylcellulose and exhibited decreased growth in 3D conditions (Fig. 6F) . However, KT13 cells expressing GFP FAK-WT, GFP FAK-R454, or bcatenin DGSK grew equivalently in tumorsphere media to parental KMF cells (Fig. 6F) . Notably, FAK R454 cells grow in 3D culture whereas parental KMF cells treated with FAKi exhibit growth defects ( Fig. 3 and Supplemental Fig. S6 ).
Nevertheless, KT13 3D tumorsphere formation was significantly enhanced by FAK-WT and b-catenin DGSK but not FAK R454 re-expression (Figs. 6G and H). FAK-WT restored total ALDEFLUOR activity, ALDH-1A2, ALDH-1B1, and Myc protein levels in FAK-/-KT13 cells equivalent to parental KMF cells (Figs. 6I and J) . Expression of FAK-WT and b-catenin DGSK but not FAK R454 significantly enhanced FAK-/-KT13 CP resistance in vitro (Fig. 6K) . Together, these results link intrinsic FAK activity and b-catenin in supporting KMF CSC and intrinsic CP resistance phenotypes in vitro.
Intrinsic FAK activity promotes KMF tumor growth
Although FAKi decreased tumor growth and inhibited secondary KMF tumor formation in mice (Fig. 4) , it remained unclear whether in vivo FAKi effects were mediated via inhibition of FAK activity in tumor, stroma, or multiple cell types. Parental KMF, FAK-/-KT13, and KT13 FAK-WT cells were labeled with a dual reporter (luciferase and dTomato) and injected within the intraperitoneal cavity of C57Bl6 mice to test whether FAK is essential for KMF tumor formation (Fig. 7A) . At Day 24, luciferase imaging revealed significant KMF tumor burden whereas FAK-/-KT13 tumors were only weakly detected ( Fig. 7A and Supplemental Fig. S17 ). Direct enumeration of dTomato-positive cells isolated from a peritoneal wash at Day 28 revealed significantly fewer FAK-/-KT13 compared to mice bearing KMF and FAK-WT tumors (Fig. 7B) . In an independent tumor experiment over 21 days, expression of FAK R454 did not promote FAK-/-KT13 tumor growth (Fig. 7C) , supporting the essential importance of FAK activity for tumor growth in vivo. Surprisingly, b-catenin DGSK also did not promote FAK-/-KT13 tumor growth (Fig. 7C ). This result contrasted with the rescue of FAK-/-KT13 tumorsphere formation, ALDEFLUOR activity, and CP resistance in vitro by b-catenin DGSK expression (Fig. 6 ). As tumor growth is a complex process, it is likely that b-catenin activation is one of several pathways downstream of FAK necessary for tumor growth.
Transcriptomic analysis of common FAK activity-dependent and b-catenin mRNA targets FAK controls various gene transcriptional networks (Serrels, McGivern et al., 2017 . As FAK-/-KT13 KMF cells are deficient in a number of different phenotypes, we performed RNA sequencing from cells grown as 3D tumorspheres to determine potential FAK activity-dependent, -independent, and b-catenin-specific patterns of differential gene expression. Analyses of FAK-/-KT13 and FAK-WT re-expressing cells revealed 2642 mRNA transcripts increased two-fold or more by FAK and significant after multiple testing correction ( Fig. 7D and Supplemental Table S10 ). By filtering out transcripts that were elevated in FAK R454 cells, 1482 genes were identified as FAK activity-dependent and showed KEGG pathway enrichment for Ribosome, Pathways in Cancer, Tumor Necrosis Factor, and Wnt Signaling. (Supplemental Table S11 ). Notably, MYC, FOXM1, and ELKF were identified as transcription factors involved in FAK activitydependent target regulation by ChIP Enrichment Analysis (ChEA) (Supplemental Table  S12 ).
RNA sequencing identified 3899 mRNA transcripts that were elevated 2-fold or more and significant after multiple testing correction by b-catenin DGSK expression in FAK-/-KT13 cells (Supplemental Table S10 ). Unbiased filtering of the 1482 FAK activitydependent transcripts with those elevated by b-catenin DGSK revealed 688 transcripts as common targets regulated by FAK activity and b-catenin (Fig. 7D and Supplemental Table  S10 ). ChEA analyses showed enhancement of ELKF, MYC and FOXM1 transcription factors with Ribosome, Pathways in Cancer, and Wnt Signaling as commonly enriched KEGG pathways. Several known targets that promote platinum resistance or stemness were identified as being regulated by FAK and b-catenin signaling in KMF cells (Table 2) . These include AMIGO2, CD44, DUSP1, FN1, and IER5 associated with platinum resistance and EIF4BP1, GAB1, LIMA1, and RCL1 associated with stemness, respectively.
Connections between FAK activity and MYC in HGSOC
To explore potential similarities between murine KMF cells and HGSOC, the 688 common FAK activity-and b-catenin-enhanced mRNA targets were filtered against genes elevated in HGSOC. Notably 639 targets (93%) were matched, 408 genes (61%) were elevated in at least 20% of TCGA tumor samples, and 66 genes were elevated-amplified in greater than 50% of patients (Supplemental Table S13 ). MYC was the most common gene target (80%) with FOXM1 and ELKF transcription factor targets enriched by ChEA analyses. KEGG enrichment analyses identified Ribosome, Pathways in Cancer, Wnt Signaling, and DNA Replication pathways. While many of these 66 genes were prognostic for poor outcome independent of FAK, the expression of immediate early response 5 (IER5) and dual specificity phosphatase 1 (DUSP1) were selectively associated with poor outcome among patients with elevated FAK expression (Fig. 7E ) (logrank P = 9.486e-3). Although a role for IER5 in ovarian cancer is not yet described, elevated DUSP1 has been linked to platinum resistance (Kang, Nagaraja et al., 2016) . Taken together, our transcriptomic and cell biological analyses of KMF cells have identified a FAK activitydependent, b-catenin and Myc associated gene signature supporting CSC and platinum resistance signaling pathways in ovarian cancer. KMF cells are a unique murine model with profound similarities to HGSOC and will be made available to the research community.
Discussion
Patients with platinum resistant ovarian cancer have minimally effective treatment options, complex tumor genomes, and few targetable oncogenic mutations (Patch et al., 2015) . Gene breakage, gains, or losses are common drivers of tumor cell phenotypes. We provide evidence from a new in vivo-evolved murine ovarian cancer model termed KMFdenoting gains in K-Ras, Myc, and FAK genes -for the functional significance of PTK2 (FAK) gains in ovarian cancer cell and tumor biology. KMF cells are notable for aggressive tumor growth, tumorsphere formation in vitro, elevated FAK Y397 phosphorylation, increased b-catenin and ALDH activities, deficiencies in p53 regulation, and increased resistance to CP cytotoxicity compared to parental ID8 cells. In both KMF and human OVCAR3 ovarian carcinoma cells, we identify tumorsphere associated non-canonical FAK signaling as supporting CSC phenotypes and intrinsic CP resistance.
Although MYC amplification at 8q24.21 is associated with a poor prognosis (GoodeChenevix-Trench et al., 2010) , less is known about PTK2 amplification at 8q24.3. We show that over 70% of HGSOC patient tumors contain gains at both PTK2 and MYC loci, that PTK2 copy number parallels FAK mRNA and protein increases, and that elevated FAK mRNA levels are associated with decreased patient disease-free survival. We have identified a set of 36 genes associated with PTK2 gain and increased frequency of HGSOC relapse. Additionally, we identify Myc as part of a set of 66 genes increased in KMF cells in a FAK kinase-dependent manner that are also elevated in the majority of HGSOC patients. Notably, in this 66 gene set, elevated PTK2, IER5, and DUSP1 expression as a group is associated with decreased HGSOC patient overall survival.
Another unexpected finding of our studies is that while platinum and taxane chemotherapy kills most ovarian tumor cells, we paradoxically find that FAK activation can occur in residual tumors of patients undergoing chemotherapy, in mouse tumors, and in isolated ovarian carcinoma tumorspheres after cisplatin chemotherapy (Fig. 7F) . Consistent with studies linking chemotherapy to increased CSC survival (Wiechert et al., 2016) , we find that FAK inhibition compromises ALDH activity and CSC generation in vitro and in vivo. Moreover, CP resistant cells can acquire FAK dependence for growth.
Our collective approaches, including pharmacological inhibition, FAK knockout, FAK re-expression, and complementation analyses show that FAK signaling sustains both intrinsic and acquired resistance to cisplatin chemotherapy in part via b-catenin activation and the elevation of MYC, FOXM1, and ELKF transcription factors supporting Wnt signaling and DNA replication genes involved in CSC survival and platinum resistance (Fig. 7F) . Interestingly, a FAK to b-catenin signaling linkage has been identified as an adaptive chemotherapy resistance pathway in BRAF mutated colon cancer (Chen, Gao et al., 2018 , Taylor & Schlaepfer, 2018 . Although stabilized b-catenin DGSK expression in KMF FAK-/-cells activated a number of canonical Wnt target genes, this was unexpectedly insufficient to rescue KMF FAK-/-growth as tumors. Instead, we show that FAK expression and intrinsic activity are essential for KMF tumor growth and that elevated FAK activity and Y397 phosphorylation is an acquired and targetable cellular adaptation of cisplatin resistance in HGSOC.
Mechanistically, FAK functions as a signaling scaffold that is recruited to different cellular compartments in response to various stimuli . It has both kinase-dependent and -independent functions in regulating gene expression (Lim et al., 2008 , Serrels et al., 2017 . It is possible that b-catenin DGSK signaling requires FAK scaffold to support tumor growth in vivo, or that this stabilized b-catenin construct only functions as a weak oncogene (Barth et al., 1999) . In cell culture, CP resistant cells acquired dependence on FAK activity to maintain proliferation as 3D tumorspheres without alterations in 2D growth. In contrast to other studies (Kolev et al., 2017) , single agent pharmacological FAK inhibition did not promote apoptosis of ovarian CP resistant cells. Rather, the combination of FAK inhibition (genomic and pharmacological) with CP triggered apoptosis of CP resistant cells as tumorspheres in vitro and prevented CPresistant tumor growth in mice. To this end, a clinical trial for recurrent CP resistant ovarian cancer termed ROCKIF (Re-sensitization of platinum-resistant Ovarian Cancer by Kinase Inhibition of FAK, NCT03287271) will test whether the small molecule FAK inhibitor defactinib, in combination with carboplatin and paclitaxel chemotherapy, can provide benefit for this difficult to treat patient population. The dTomato with luciferase lentiviral vector, pUltra-Chili-Luc, was a gift from Malcolm Moore (Addgene #48688). The lentiviral vector MSCV-b-catenin (DGSK-KT3)-IRES-GFP was a gift from Tannishtha Reya (Addgene #14717). The CRISPR/Cas9 plasmid pSpCas9n(BB)-2A-Puro was a gift from Feng Zhang (Addgene #48141). Lentiviral vectors for GFP-FAK wildtype and FAK kinase-dead (R454) in pCDH-CMV-MCS-Puro (System Biosciences) were used as described (Chen et al., 2012) . FAKi VS-4718 and VS-6063 (defactinib) were from Verastem Inc. FAKi, cisplatin (Enzo Life Sciences), JQ1 (MedChemExpress), MLN8237 (Selleckchem), MSAB (Sigma), wortmannin (Sigma), U0126 (Sigma) or staurosporine (Calbiochem) were dissolved in DMSO for in vitro studies. VS-4718 was suspended in 0.5% carboxymethyl cellulose (Sigma) and 0.1% Tween 80 (Sigma) in sterile water and administered twice daily by oral gavage for tumor experiments. Cisplatin and paclitaxel (APP Pharmaceuticals) were from the UCSD Moores Cancer Center Pharmacy.
Cells
Human ovarian carcinoma A2780, A2780-CP70, and OVCAR10 cell lines were from Denise Connolly (Fox Chase Cancer Center, PA). NIH OVCAR3 cells were from the Division of Cancer Treatment & Diagnosis Tumor Repository, National Cancer Institute (Frederick, MD), murine ovarian ID8 cells were from Katherine Roby (University of Kansas Medical Center), and KMF cells were isolated from peritoneal ascites of ID8-injected C57Bl6 tumor-bearing mice as described (Ward et al., 2013) . Intermittent CP exposure (10 µM for 24 h), cell recovery (7 days), and repeated exposure-recovery (5 times) was used to generate OVCAR10-CP cells.
OVCAR3 FAK knockout cells were generated using CRISPR/Cas9 targeting. pSpCas9n(BB)-2A-Puro was used to deliver guide RNAs (ACTGGTATGGAACGTTCTCC and TGAGTCTTAGTACTCGAATT) targeting exon 3 of human PTK2. Transfected cells were enriched by puromycin (1 µg/ml, 3 days) and clones selected by dilution. Loss of FAK expression was verified by immunoblotting. DNA sequencing was used to verify insertions/deletions introducing stop codons in PTK2 exon 3. FAK re-expressing cells were generated by lentiviral transduction of OVCAR3 FAK KO clone AB21, puromycin selection, enrichment by flow cytometry, and GFP-FAK protein expression verified by immunoblotting. KMF FAK knockout cells were generated by CRISPR/Cas9 targeting. pSpCas9n(BB)-2A-Puro was used to deliver two independent guide RNAs (ACTTACATGGTAGCTCGCGG and CACTCCCACAGCCATCCTAT) targeting exon 4 of murine PTK2. Transfected cells were enriched by puromycin selection (3.5 µg/mL for 24 h) and clones selected by dilution. Loss of FAK expression was verified by immunoblotting. DNA sequencing was used to verify insertions/deletions introducing stop codons in murine PTK2 exon 4.
GFP-FAK-WT, GFP-FAK-R454, and DGSK b-catenin (GFP expressed independently) were generated by lentiviral (for FAK) or retroviral (for b-catenin DGSK) transduction, puromycin or hygromycin selection, enrichment by flow cytometry, and protein expression verified by immunoblotting. For adherent 2D growth, cells were maintained in DMEM (OVCAR10, OVCAR10-CP, ID8, and KMF) or RPMI 1640 (A2780, A2780-CP70, and OVCAR3) supplemented with 10% fetal bovine serum (FBS, Omega Scientific), 1 mM non-essential amino acids, 100 U/ml penicillin, and 100 µg/ml streptomycin on cell culture-treated plastic plates (Costar). For growth as tumorspheres, cells were seeded in poly-hydroxyethyl methacrylic acid (poly-HEMA) coated Costar plates (non-adherent) in serum-free CSC media (3D Tumorsphere Medium XF, PromoCell GmbH) at dilutions recommended by the manufacturer. Prior to tumor initiation experiments, KMF, A2780, and A2780-CP70 cells were transduced with a lentiviral vector expressing dTomato and luciferase (pUltra-Chili-Luc) or mCherry (pCDH-CMV-MSCI) and enriched by fluorescence sorting.
2D and 3D Cell Growth Assays
For 2D growth, cells were seeded (3x10 5 cells per well) in tissue culture-treated 6-well plates (Costar). At the indicated time, cells were enumerated and stained with Trypan blue (ViCell XR, Beckman). Alternatively, cell metabolic activity was measured by a colorimetric XTT assay (Sigma). For 3D tumorspheres, cells were seeded at 10,000 cells/ml equivalent in poly-HEMA-coated 6-, 24-, or 96-well plates (Costar) for 5 days. At the indicated times, 3D tumorspheres were phase-contrast imaged (Olympus CKX41), enumerated (ViCell XR), or collected by centrifugation. Spheroid size was determined using Image J (NIH). Alternatively, cell metabolic activity was measured by a colorimetric XTT assay (Sigma). For methylcellulose colony formation, cells were suspended in 1% methylcellulose diluted in 2D growth media, 10 4 plated in 6-well poly-HEMA-coated plates, and colony formation analyzed after 21 days. Cells from methylcellulose colonies were collected by dilution-dispersion in PBS, centrifugation at 400 xg, and washed in PBS prior to enumeration or cell lysis. Cells were used at passage 10 to 35 and mycoplasma testing was performed every 3 months.
Patient Tumor Samples
De-identified human OC tissue specimens from consented patients were obtained from the Fox Chase Cancer Center (FCCC) Biosample Repository Facility (BRF) under Institutional Review Board (IRB) approved protocols . FCCC staff queried the BRF sample database to identify participants that received carboplatin and paclitaxel neoadjuvant chemotherapy. Biopsy specimens were obtained from FCCC Surgical Pathology, sectioned, H&E stained, and reviewed by a board-certified pathologist. FFPE blocks from the biopsy and the corresponding surgical resection blocks banked by the BRF were cut to obtain one H&E stained slide and six additional unstained sections. One section each from pre-treatment biopsy and post-neoadjuvant treatment surgical resection specimen was stained for Pax8 by the FCCC Histopathology Facility. The remainder of unstained slides were sent to UCSD for additional staining performed under UCSD IRB-approved protocol (IRB 110805).
Immunohistochemistry
Mouse tumors were divided into thirds and either processed for protein lysates, fixed in formalin, or frozen in optimal cutting temperature compound. For immunohistochemical staining, paraffinembedded tumors were sectioned, mounted onto glass slides, deparaffinized, rehydrated, processed for antigen retrieval, and peroxidase quenched as described (Tancioni et al., 2014) . Tissues were blocked (PBS with 1% BSA, and 0.1% Triton X-100) for 45 minutes at room temperature and incubated with anti-PAX8 (1:200), anti-FAK (1:200), anti-Ki67 (1:500), anti-active b-catenin (1:800) or anti-pY397 FAK (1:100) in blocking buffer overnight. FAK pY397 antibodies were pre-incubated with 200-fold molar excess of FAK pY397 peptide (Abcam) for 12 hours at RT prior to use in IHC staining. Processing with biotinylated goat-anti-rabbit or goat-anti-mouse IgG, Vectastain ABC Elite, and diaminobenzidine were used to visualize antibody binding. Slides were counterstained with hematoxylin. Colon or breast carcinoma tumor samples were used as controls for active b-catenin staining. High resolution digital scans were acquired (Aperio CS2 scanner) using Image Scope software (Leica Biosystems). Images were also acquired using an upright microscope (Olympus BX43) with a color camera (Olympus SC100). A board-certified pathologist evaluated H&E, Pax8, pY397 FAK, or Ki67 stained images of patient tumor samples in a blinded manner. Quantification was performed using Aperio Image Analysis software (v12.3.0.5056) using the positive pixel count (v9) algorithm. Pax8-positive regions were identified and then these regions were manually-transposed onto images from FAK pY397-stained serial section slides. Average intensity (I-avg) values were obtained and percent FAK pY397 was calculated.
Frozen tumors were thin sectioned (7 µm) using a cryostat (Leica), mounted onto glass slides, fixed with acetone (or with 4% paraformaldehyde) for 10 min, permeabilized (PBS with 0.1% Triton) for 1 minute, and blocked (PBS with 8% goat serum) for 2 hours at room temperature. Sections were incubated in anti-ALDH1A1 (1:100) or anti-pY397 FAK (1:100) in PBS with 2% goat serum overnight. Antibody binding was detected with goat anti-rabbit conjugated with Alexa Fluor-488. Cell nuclei were visualized using Hoechst 33342 stain (Thermo). Images were sequentially captured at 20X magnification (UPLFL objective, 1.3 NA; Olympus) using a monochrome charge-coupled camera (ORCA ER; Hamamatsu), an inverted microscope (IX81; Olympus), and Slidebook software (v5.0, Intelligent Imaging). Images were pseudo-colored, overlaid, merged using Photoshop (Adobe), and quantified using Image J (NIH).
Statistics
Statistical difference between groups was determined using one-way or two-way ANOVA with Tukey, Bonferroni's or Fisher's LSD post hoc analysis. Differences between pairs of data were determined using an unpaired two-tailed Student's t test. For the IHC analysis the differences between pairs of data were calculated using a paired two-tailed Student's t test. All statistical analyses were performed using Prism (GraphPad Software, v7 The Paper Explained Problem: Ovarian cancer remains the leading cause of death from gynecologic malignancies. Although platinum-based chemotherapy is part of standard-of-care treatment and is effective at creating DNA adducts and triggering cell apoptosis, subpopulations of tumor cells can survive this stress. Three in four women with high grade serous ovarian cancer (HGSOC) will recur, develop platinum resistance, and succumb to disease. Approaches to re-sensitize these tumors to platinum chemotherapy, or prevent tumor escape, are critically needed.
The PTK2 gene at 8q24.3, encoding focal adhesion kinase (FAK), is frequently amplified in ovarian tumors. FAK is a cytoplasmic tyrosine kinase promoting cell survival signaling. FAK is associated with HGSOC progression, but the determinants of FAK pathway dependence in tumors remain unknown.
Results:
We molecularly characterize a new murine model of ovarian cancer that displays spontaneous acquired similarities to HGSOC, including gains in the K-Ras, Myc, and FAK genes (KMF). Our collective approaches in human ovarian carcinoma and KMF cells, including pharmacological inhibition, FAK knockout, FAK re-expression, complementation, and bioinformatic analyses reveal that FAK signaling sustains both intrinsic and acquired resistance to platinum chemotherapy in part via b-catenin activation and the elevation of MYC, FOXM1, and ELKF (KLF1) transcription factors supporting Wnt signaling and DNA replication genes involved in cancer stem cell survival and platinum resistance. FAK is unexpectedly activated in KMF and HGSOC tumor cells surviving neoadjuvant chemotherapy and we find that this is an acquired and targetable cellular adaptation of platinum resistance. The combination of FAK inhibition (genomic & pharmacologic) with cisplatin triggered apoptosis of platinum-resistant cells as tumorspheres in vitro and in orthotopic models in vivo. Gene editing and rescue approaches confirmed that intrinsic FAK activity is essential for tumor growth in mice.
Impact:
We identified a set of 36 genes associated with PTK2 gain and increased frequency of HGSOC relapse. Moreover, a set of 66 genes including Myc were elevated in a FAK kinase dependent manner correspond to genes gained in the majority of HGSOC patients. Within this gene set, increased IER5 and DUSP1 expression are associated with decreased survival of patients bearing 8q24.3 gains. A clinical trial for recurrent platinum resistant ovarian cancer termed ROCKIF (Re-sensitization of platinum-resistant Ovarian Cancer by Kinase Inhibition of FAK, NCT03287271) will test whether the small molecule FAK inhibitor defactinib, in combination with carboplatin and paclitaxel chemotherapy, can provide benefit for this difficult to treat patient population.
Data Availability
The Exome sequencing FASTA files have been deposited to the NCBI Gene Expression Omnibus under the accession numbers [in progress]. The RNA-Sequencing FASTQ files used in this paper have been deposited to the NCBI Gene Expression Omnibus under the accession numbers [in progress]. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Perez-Riverol, Csordas et al., 2019) partner repository with the dataset identifier PXD013062. Figures (full legend on figure)  Fig. S1 . List of ID8 and ID8-IP/KMF gene variants identified by exome sequencing. Fig. S2 . Analysis of MYC and PTK2 mRNA and protein expression as a function of genomic copy number. Fig. S3 . Deficient p53 regulation in KMF cells. Fig. S4 . Characterization of ID8 and KMF cells. Fig. S5 . FAK pY397 phosphorylation is maintained in Pax8-positive HGSOC tumors after neo-adjuvant chemotherapy. Fig. S6 . Small molecule FAK inhibition selectively prevents KMF 3D tumorsphere proliferation with effects on cell cycle but not cell apoptosis. Fig. S7 . Small molecule FAK inhibition selectively prevents OVCAR3 3D tumorsphere proliferation with effects on cell cycle but not cell apoptosis. Tables  Table S1. ID8 unique unique variants listed and filtered. Table S2 . ID8-IP / KMF unique variants listed and filtered. Values are means (± SEM, **, P <0.01, *** P <0.001, two-way ANOVA with a Bonferroni's multiple comparisons test) from 3 independent experiments. EC50 values were determined independently and calculated using Prism (Graphpad). This represents FAK scaffold or activity-independent group (blue). By subtraction of FAK R454 from FAK-WT targets, 1482 FAK activity-dependent targets were identified (green). 3899 mRNAs were elevated in DGSK b-catenin KT13 FAK-/-cells and by filtering against FAK activity mRNAs, 688 common FAK activity and b-catenin enhanced mRNA targets were identified (red). 639 of 688 murine KMF targets were matched to genes elevated in HGSOC. 408 targets were elevated in 20% of HGSOC patients and 66 targets were elevated in more than 50% of HGSOC patients. MYC and FAK show the highest frequency of genetic gain. Representative transcription factors identified by ChIP Enrichment Analysis (ChEA) and the top 5 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichments are listed for filtered groups. (E) Kaplan-Meier analysis of the impact of expression of DUSP1 and IER5 (z>0.1) on overall patient survival expressing elevated (z>3) or lesser levels of FAK mRNA. (F) Signaling summary of death-inducing and paradoxical survival-sustaining FAK activation by platinum chemotherapy. FAK signaling to b-catenin, MYC, FOXM1, and KLF1 transcription factors support elevated mRNA levels for CSC and DNA repair genes hypothesized to support cellular resistance platinum DNA damage. Tumor cell intrinsic FAK kinase activity is essential for KMF tumor growth via signaling in a context-dependent manner. ABLIM3  DUSP1  HMGA1  IER5  AMIGO2  FHL2  IER3  PMM1  CD44  FN1  SLC43A3  DIO2   Stemness  ACAT2  EIF4BP1  GCAT  LAPTM4B  NOP56  EIF4BP1  BYSL  ELOVL6  CRWD  LIMA1  PLA2G6  ELOVL6  CTBP2  GAB1  INTS5  LSM2  RCL1  GAB1  SLC38A2 
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